Verastem Inc represents a commitment to advancing science and innovation in oncology. With a focus on developing novel therapies for cancer patients, the company's corporate philosophy centers around delivering transformative medicines to improve outcomes and quality of life. Verastem Inc strives to push the boundaries of cancer research by leveraging its expertise in small molecule targeting. Through its dedication to precision medicine and patient-centered approaches, Verastem Inc aims to make a lasting impact in the fight against cancer.

Verastem Inc primarily operates in the United States.

Verastem Inc has achieved several significant milestones. The company successfully developed and gained approval for its first-in-class small molecule cancer therapy, known as duvelisib. This marked an important achievement in Verastem's goal of treating patients with various types of cancer. Additionally, Verastem has made significant progress in advancing clinical trials, expanding its pipeline, and strengthening its research and development capabilities. The company's collaborations with leading research institutions and pharmaceutical companies have also contributed to its growth and success in the field of oncology. Overall, Verastem Inc has reached important milestones through its innovative therapies and strategic partnerships.

Verastem Inc. is a biopharmaceutical company specializing in the development of small molecule drugs to treat cancer. Founded in 2010, Verastem is headquartered in Needham, Massachusetts. The company focuses on discovering and advancing targeted therapies that inhibit the function of cancer stem cells. Verastem's lead product, duvelisib, is an oral small molecule inhibitor used for the treatment of certain types of blood cancers. With a strong emphasis on research and development, Verastem aims to improve patient outcomes and transform cancer treatment. As a trusted name in the biopharmaceutical industry, Verastem Inc. continues to make significant contributions in the fight against cancer.

The main competitors of Verastem Inc in the market include companies such as Bristol-Myers Squibb, Merck & Co., and AstraZeneca.

Verastem Inc is primarily active in the pharmaceutical industry.

Verastem Inc is a biopharmaceutical company that focuses on developing and commercializing novel drugs to improve the outcomes of patients with cancer. Their business model revolves around leveraging their expertise in small molecule drugs and targeting cancer stem cells. By identifying and targeting these cells, Verastem aims to develop innovative therapies that can effectively treat various types of cancer. Through their strategic collaborations and clinical trials, the company strives to bring transformative treatments to patients, ultimately providing them with better chances of survival and improved quality of life. Verastem Inc adopts a patient-centric approach in their business model, constantly aiming to address unmet medical needs in the oncology field.

Verastem hissesinin F/K oranı -0,47.

Verastem KUV 9,39 dir.

Verastem için AlleAktien Kalite Skoru 4/10'dur.

beklenen Verastem cirosu 6,58 Milyon. USD dir.

beklenen Verastem karı -131,24 Milyon. USD olarak gerçekleşmiştir.

Verastem Inc is a company that focuses on the development and marketing of drugs for the treatment of cancer and other serious diseases. It was founded in 2010 and is headquartered in Needham, Massachusetts. The company's business model is based on the identification and validation of target molecules that are important in fighting cancer. Verastem uses modern technologies such as genetic modification and RNA interference to identify these target molecules and study their role in cancer growth. The company has several divisions, including the discovery and development of drugs targeting molecules found in cancer cells, the development of diagnostic and prognostic tools, and collaborations with other pharmaceutical companies, research institutes, and treatment centers. Verastem has developed drugs such as Copiktra for the treatment of certain types of leukemia and lymphomas, and VS-6766 for the treatment of various tumor types including colon cancer and nervous system tumors. The company aims to develop innovative solutions for the treatment of cancer patients by identifying target molecules that are important for tumor growth. Copiktra and VS-6766 are examples of drugs developed by Verastem to help cancer patients.

Verastem, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Verastem için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Verastem şirketinin ISIN kodu US92337C1045’dir.

Verastem 'nin WKN'si A1JTPU 'dir.

Verastem için Ticker VSTM’dir.

Son 12 ay içerisinde Verastem, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Verastem, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Verastem şirketinin mevcut temettü verimi .

Verastem dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Verastem, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Verastem, 'Sağlık' sektörüne atanmıştır.

Son Verastem tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 13.09.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 13.09.2024 olarak gerçekleşti.

2023 yılında Verastem tarafından 0 USD olarak temettüler dağıtıldı.

Verastem hisselerinin temettüleri USD olarak dağıtılır.